AI-generated summary
This randomized, placebo-controlled trial enrolled 81 patients with smell impairment after COVID-19 and assigned them to control, red light or infrared light photobiomodulation groups, all with corticosteroids and olfactory training. The authors report that infrared therapy was associated with greater improvement in UPSIT smell test scores than controls, and that no major adverse events occurred. The study is described as proof-of-concept, so its findings are preliminary.
- Participants
- 81
- Who or what was studied
- Patients with olfactory disorders 1 to 12 months after SARS-CoV-2 infection
- Limits stated in the abstract
- The study is described as proof-of-concept, and the abstract reports no details on blinding or long-term follow-up beyond three months.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objectives
Photobiomodulation Therapy (PBMT) is a non-invasive treatment that uses photons from the red to infrared spectrum to modulate cellular processes with anti-inflammatory and regenerative properties. This study aimed to evaluate the use of PBMT applied intranasally in patients with an impaired sense of smell after COVID-19.
Methods
This proof-of-concept study was a randomized, placebo-controlled clinical trial that recruited 81 patients with olfactory disorders after SARS-CoV-2 infection (1-12 months), randomly assigned to 3 groups: controls, red light and infrared light exposure groups. PBMT was applied twice a week for five weeks, associated with prednisolone 40 mg for five days and olfactory training for 90 days from the first day of laser application. UPSIT® and subjective chemosensory scores were the outcomes collected before the first session and three months thereafter.
Results
Compared to controls, patients undergoing infrared PBMT showed more improvement in UPSIT® scores (+4.6 points, 95% CI: 1.5-7.8, p = 0.004) and a tendency towards reporting a better subjective smell score at the three-month follow-up. Response rates were 26.1% (95% CI: 6.7-45.5), 43.5% (95% CI: 21.6-65.4), and 68% (95% CI: 48.3-87.7) in the control, red and infrared groups, respectively. No major adverse events were reported.
Conclusion
Therapy with PBMT in the infrared frequency appears to be a safe option in treating post-COVID olfactory disorders when combined with a five-day use of systemic corticosteroid and 90 days of olfactory training.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Randomized controlled trial, Placebo-controlled, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.